Vaccine-induced mucosal immunity to poliovirus: analysis of cohorts from an open-label, randomised controlled trial in Latin American infants

The Lancet Infectious Diseases

Volumn 16, Issue 12, 2016, Pages 1377-1384

  Wright, Peter F ^a   Connor, Ruth I ^a   Wieland Alter, Wendy F ^a   Hoen, Anne G ^b   Boesch, Austin W ^c   Ackerman, Margaret E ^c   Oberste, M Steven ^d   Gast, Chris ^e   Brickley, Elizabeth B ^b   Asturias, Edwin J ^f   Rüttimann, Ricardo ^g   Bandyopadhyay, Ananda S ^h  

^a DARTMOUTH COLLEGE   (United States)

^b DARTMOUTH MEDICAL SCHOOL   (United States)

^c DARTMOUTH COLLEGE   (United States)

^d CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^e USA   (United States)

^f UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^g Fighting Infectious Diseases in Emerging Countries (FIDEC)   (United States)

^h BILL AND MELINDA GATES FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INACTIVATED POLIOVIRUS VACCINE; INACTIVATED VACCINE; NEUTRALIZING ANTIBODY; ORAL POLIOVIRUS VACCINE; POLIOMYELITIS VACCINE; UNCLASSIFIED DRUG; VIRUS ANTIBODY;

AMERICAN; ANTIBODY TITER; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DOMINICAN REPUBLIC; FECES ANALYSIS; GUATEMALA; HUMAN; IN VITRO STUDY; INFANT; MAJOR CLINICAL STUDY; MUCOSAL IMMUNITY; OPEN STUDY; POLIOMYELITIS VIRUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VACCINATION; VIRUS NEUTRALIZATION; VIRUS SHEDDING; BLOOD; COMBINATION DRUG THERAPY; FECES; IMMUNIZATION; IMMUNOLOGY; ISOLATION AND PURIFICATION; POLIOMYELITIS; SEROTYPE; SOUTH AND CENTRAL AMERICA; VIROLOGY;

ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; DRUG THERAPY, COMBINATION; FECES; HUMANS; IMMUNITY, MUCOSAL; IMMUNIZATION SCHEDULE; LATIN AMERICA; POLIOMYELITIS; POLIOVIRUS; POLIOVIRUS VACCINES; SEROGROUP; VACCINATION; VIRUS SHEDDING;

EID: 84994890050     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(16)30169-4     Document Type: Article

References (25)

1. 1 Bandyopadhyay, AS, Garon, J, Seib, K, Orenstein, WA, Polio vaccination: past, present and future. Future Microbiol 10 (2015), 791–808.
2. 2 Modlin, J, Wenger, J, Achieving and maintaining polio eradication—new strategies. N Engl J Med 371 (2014), 1476–1479.
3. 3 Landaverde, JM, Trumbo, SP, Danovaro-Holliday, MC, Cochi, SE, Gandhi, R, Ruiz-Matus, C, Vaccine-associated paralytic poliomyelitis in the postelimination era in Latin America and the Caribbean, 1992–2011. J Infect Dis 209 (2014), 1393–1402.
4. 4 Dunn, G, Klapsa, D, Wilton, T, Stone, L, Minor, PD, Martin, J, Twenty-Eight Years of poliovirus replication in an immunodeficient individual: impact on the Global Polio Eradication Initiative. PLoS Pathog, 11, 2015, e1005114.
5. 5 Burns, CC, Shaw, J, Jorba, J, et al. Multiple independent emergences of type 2 vaccine-derived polioviruses during a large outbreak in northern Nigeria. J Virol 87 (2013), 4907–4922.
6. 6 Ogra, PL, Karzon, DT, Righthand, F, MacGillivray, M, Immunoglobulin response in serum and secretions after immunization with live and inactivated poliovaccine and natural infection. N Engl J Med 279 (1968), 893–900.
7. 7 Herremans, TM, Reimerink, JH, Buisman, AM, Kimman, TG, Koopmans, MP, Induction of mucosal immunity by inactivated poliovirus vaccine is dependent on previous mucosal contact with live virus. J Immunol 162 (1999), 5011–5018.
8. 8 Onorato, IM, Modlin, JF, McBean, AM, Thoms, ML, Losonsky, GA, Bernier, RH, Mucosal immunity induced by enhance-potency inactivated and oral polio vaccines. J Infect Dis 163 (1991), 1–6.
9. 9 Modlin, JF, Halsey, NA, Thoms, ML, Meschievitz, CK, Patriarca, PA, Humoral and mucosal immunity in infants induced by three sequential inactivated poliovirus vaccine-live attenuated oral poliovirus vaccine immunization schedules. Baltimore Area Polio Vaccine Study Group. J Infect Dis 175:suppl 1 (1997), S228–S234.
10. 10 WHO Collaborative Study Group on Oral and Inactivated Poliovirus Vaccines. Combined immunization of infants with oral and inactivated poliovirus vaccines: results of a randomized trial in The Gambia, Oman, and Thailand. J Infect Dis 175:suppl 1 (1997), S215–S227.
11. 11 Cuba IPV Study Collaborative Group. Randomized, placebo-controlled trial of inactivated poliovirus vaccine in Cuba. N Engl J Med 356 (2007), 1536–1544.
12. 12 Sutter, RW, Bahl, S, Deshpande, JM, et al. Immunogenicity of a new routine vaccination schedule for global poliomyelitis prevention: an open-label, randomised controlled trial. Lancet 386 (2015), 2413–2421.
13. 13 John, J, Giri, S, Karthikeyan, AS, et al. Effect of a single inactivated poliovirus vaccine dose on intestinal immunity against poliovirus in children previously given oral vaccine: an open-label, randomised controlled trial. Lancet 384 (2014), 1505–1512.
14. 14 Anand, A, Zaman, K, Estívariz, CF, et al. Early priming with inactivated poliovirus vaccine (IPV) and intradermal fractional dose IPV administered by a microneedle device: a randomized controlled trial. Vaccine 33 (2015), 6816–6822.
15. 15 O'Ryan, M, Bandyopadhyay, AS, Villena, R, et al., the Chilean IPV/bOPV study group. Inactivated poliovirus vaccine given alone or in a sequential schedule with bivalent oral poliovirus vaccine in Chilean infants: a randomised, controlled, open-label, phase 4, non-inferiority study. Lancet Infect Dis 15 (2015), 1273–1282.
16. 16 Asturias, EJ, Bandyopadhyay, AS, Self, S, et al. Humoral and intestinal immunity induced by new schedules of bivalent oral poliovirus vaccine and one or two doses of inactivated poliovirus vaccine in Latin American infants: an open-label randomised, controlled trial. Lancet 388 (2016), 158–169.
17. 17 Duintjer Tebbens, RJ, Pallansch, MA, Chumakov, KM, et al. Expert review on poliovirus immunity and transmission. Risk Anal 33 (2013), 544–605.
18. 18 Wright, PF, Wieland-Alter, W, Ilyushina, NA, et al. Intestinal immunity is a determinant of clearance of poliovirus after oral vaccination. J Infect Dis 209 (2014), 1628–1634.
19. 19 Arita, M, Iwai, M, Wakita, T, Shimizu, H, Development of a poliovirus neutralization test with poliovirus pseudovirus for measurement of neutralizing antibody titre in human serum. Clin Vaccine Immunol 18 (2011), 1889–1894.
20. 20 Shulman, LM, Martin, J, Sofer, D, et al. Genetic analysis and characterization of wild poliovirus type 1 during sustained transmission in a population with 95% vaccine coverage, Israel 2013. Clin Infect Dis 60 (2015), 1057–1064.
21. 21 Cerutti, A, Chen, K, Chorny, A, Immunoglobulin responses at the mucosal interface. Annu Rev Immunol 29 (2011), 273–293.
22. 22 McIntosh, K, McQuillin, J, Gardner, PS, Cell-free and cell-bound antibody in nasal secretions from infants with respiratory syncytial virus infection. Infect Immun 23 (1979), 276–281.
23. 23 Nathanson, N, The pathogenesis of poliomyelitis: what we don't know. Adv Virus Res 71 (2008), 1–50.
24. 24 Hird, TR, Grassly, NC, Systematic review of mucosal immunity induced by oral and inactivated poliovirus vaccines against virus shedding following oral poliovirus challenge. PLoS Pathog, 8, 2012, e1002599.
25. 25 Jafari, H, Deshpande, JM, Sutter, RW, et al. Polio eradication. Efficacy of inactivated poliovirus vaccine in India. Science 345 (2014), 922–925.